Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eftilagimod alpha + paclitaxel
- Development stage
- Unknown
- Lead developer
- Immutep
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Eftilagimod alpha (efti) + paclitaxel is a combination therapy consisting of a soluble lymphocyte activation gene-3 (LAG-3) protein and a standard chemotherapy agent. Efti functions as an MHC class II agonist that enhances both innate and adaptive immunity by activating antigen-presenting cells (APCs), which leads to CD8+ T cell activation and proliferation. This combination has been primarily investigated for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer, particularly in patients who have developed resistance to endocrine-based therapies.
- Other names
- efti + paclitaxel
02
Targets
MicrotubuleMHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on eftilagimod alpha + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eftilagimod alpha + paclitaxel.